E2F2 Human Pre-designed siRNA Set A contains three designed siRNAs for E2F2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

E2F3 Human Pre-designed siRNA Set A contains three designed siRNAs for E2F3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

E2F4 Human Pre-designed siRNA Set A contains three designed siRNAs for E2F4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

E2F5 Human Pre-designed siRNA Set A contains three designed siRNAs for E2F5 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

E2F6 Human Pre-designed siRNA Set A contains three designed siRNAs for E2F6 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

E2F7 Human Pre-designed siRNA Set A contains three designed siRNAs for E2F7 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

E2F8 Human Pre-designed siRNA Set A contains three designed siRNAs for E2F8 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

E3 ligase Ligand 24 (Compound 24) is a Potent Ligand for the E3 Ligase DCAF15 (IC50= 0.053 μM). Due to E3 ligase Ligand 24’s selectivity and potent binding characteristics, it is pivotal in the study of targeted protein degradation[1].

E4F1 Human Pre-designed siRNA Set A contains three designed siRNAs for E4F1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

E7130 is a microtubule inhibitor, which ameliorates the tumor microenvironment through suppression of cancer-associated fibroblasts (CAF) and promotion of tumor vasculature remodeling[1].

EAF1 Human Pre-designed siRNA Set A contains three designed siRNAs for EAF1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

EAF2 Human Pre-designed siRNA Set A contains three designed siRNAs for EAF2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

EAPP Human Pre-designed siRNA Set A contains three designed siRNAs for EAPP gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

EARS2 Human Pre-designed siRNA Set A contains three designed siRNAs for EARS2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

EBAG9 Human Pre-designed siRNA Set A contains three designed siRNAs for EBAG9 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Ebastine-d6 is deuterated labeled Ebastine (HY-B0674). Ebastine (LAS-W 090) is an orally active, second-generation histamine H1 receptor antagonist. Ebastine can be used for the symptoms of allergic rhinitis and chronic idiopathic urticaria research[1].

Ebelactone A is a mycolic acid β-lactone, which exhibits inhibitory activity for esterase, lipase, fMet aminopeptidase (fMet AP) and PNBase, with IC50s of 56, 3, 8 and 7.5 μM, respectively[1]. Ebelactone A inhibits cutinase, exhibits plants protective potency against Erysiphe graminis[2].

EBET-1055 is a bromodomain and extra-terminal (BET) protein degrader (EBET) composed of a BET inhibitor (EBET-590, HY-161387), an E3 ubiquitin ligase ligand and connectors. EBET-1055 effectively inhibits the growth of pancreatic ductal adenocarcinoma (PDAC). EBET-1055 also simultaneously modulates cancer-associated fibroblast (CAF) activity, upregulating all reporter gene activities in organoid co-cultures[1].

EBET-590 is a BET inhibitor, and can be used for cancer research[1]

EBF1 Human Pre-designed siRNA Set A contains three designed siRNAs for EBF1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

EBF2 Human Pre-designed siRNA Set A contains three designed siRNAs for EBF2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

EBF3 Human Pre-designed siRNA Set A contains three designed siRNAs for EBF3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

EBF4 Human Pre-designed siRNA Set A contains three designed siRNAs for EBF4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

EBI3 Human Pre-designed siRNA Set A contains three designed siRNAs for EBI3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Ebiratide (HOE-427 free base) is a synthesized ACTH derivative, which acts directly on the central nervous system and exhibits memory-enhancing efficacy[1].

EBNA1BP2 Human Pre-designed siRNA Set A contains three designed siRNAs for EBNA1BP2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

EBOV-IN-2 (Compound 2) is an inhibitor of Ebola virus (EBOV) with IC50 values of 0.37 μM and 2.54 against Ebola virus glycoprotein pseudotype virus (pEBOV) and African swine fever virus (ASFV), respectively[1].

EBOV-IN-3 (compound 9) is benzothiazepine compound. EBOV-IN-6 has anti-pEBOV activity with a IC50 value of 0.37 μM[1].

EBOV-IN-4 (compound 12), a benzothiazepine, is a potent Ebola virus (EBOV) inhibitor with 64.9% inhibitory for EBOV-GP-pseudotype virus (pEBOV) with 10 μM. EBOV-IN-4 is inactive with ASFV[1].

EBOV-IN-5 (compound 14) is an antiviral agent that inhibits Ebola virus (EBOV) infection. EBOV-IN-5 inhibits the binding of the EBOV glycoprotein EBOV-GPcl to NPC1, an indispensable host receptor required for viral fusion/entry.[7][1].

EBOV-IN-6 (compound 19) is benzothiazepine compound. EBOV-IN-6 has anti-pEBOV activity with a IC50 value of 10 μM[1].

EBOV-IN-7 (compound 26) is an inhibitor of the Ebola virus EBOV with an IC50 of 2.04 μM against EBOV-GP pseudotyped virus (pEBOV). EBOV-IN-7 has inhibitory effects on cancer cells and inhibits the EBOV-GPcl/NPC1 interaction.[8][1].

EBP Human Pre-designed siRNA Set A contains three designed siRNAs for EBP gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

EBP-IN-1 (compound 11) is an inhibitor of emopamil-binding protein (EBP), a sterol isomerase in the cholesterol biosynthetic pathway. EBP-IN-1 has a long half-life in rodents and has good metabolic turnover and brain penetration properties. EBP-IN-1 enhances oligodendrocyte formation in human cortical organoids[1].

EBPL Human Pre-designed siRNA Set A contains three designed siRNAs for EBPL gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PF-06873600 is a selective and orally bioavailable inhibitor of cyclin-dependent kinase (CDK), with Ki values of 0.09 nM, 0.13 nM and 0.16 nM for CDK2, CDK4 and CDK6, respectively. PF-06873600 has potential antineoplastic activity[1][2].

PF-06873600 is a selective and orally bioavailable inhibitor of cyclin-dependent kinase (CDK), with Ki values of 0.09 nM, 0.13 nM and 0.16 nM for CDK2, CDK4 and CDK6, respectively. PF-06873600 has potential antineoplastic activity[1][2].

PF-06873600 is a selective and orally bioavailable inhibitor of cyclin-dependent kinase (CDK), with Ki values of 0.09 nM, 0.13 nM and 0.16 nM for CDK2, CDK4 and CDK6, respectively. PF-06873600 has potential antineoplastic activity[1][2].

PF-06873600 is a selective and orally bioavailable inhibitor of cyclin-dependent kinase (CDK), with Ki values of 0.09 nM, 0.13 nM and 0.16 nM for CDK2, CDK4 and CDK6, respectively. PF-06873600 has potential antineoplastic activity[1][2].